Ossur hf
CSE:OSSR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its 3-Year Average (22.1), the stock would be worth kr26 (1% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 22.5 | kr26.4 |
0%
|
| 3-Year Average | 22.1 | kr26 |
-1%
|
| 5-Year Average | 23 | kr27.01 |
+2%
|
| Industry Average | 22.1 | kr26.01 |
-1%
|
| Country Average | 17.5 | kr20.6 |
-22%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| IS |
O
|
Ossur hf
CSE:OSSR
|
11.3B DKK | 22.5 | 31.2 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
162.6B USD | 65.3 | 56.9 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
155.4B USD | 29 | 24.8 | |
| US |
|
Stryker Corp
NYSE:SYK
|
112.7B USD | 20.7 | 34.7 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
102.7B USD | 27.3 | 22.3 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
83.8B USD | 29.3 | 23.5 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.8B USD | 37 | 44.5 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.3B EUR | 41.4 | 18.6 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.2B USD | 46 | 42.7 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.5B USD | 17.6 | 24.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
29.9B USD | 17.2 | 20.1 |
Market Distribution
| Min | 3 |
| 30th Percentile | 10.7 |
| Median | 17.5 |
| 70th Percentile | 22.1 |
| Max | 109 |
Other Multiples
Ossur hf
Glance View
Össur hf. is an Icelandic company that stands as a quiet marvel in the realm of orthopedic innovation, specializing in the development of non-invasive equipment designed to enhance human mobility. Born out of a small prosthetics shop in Reykjavik in 1971, the company has grown into a global leader in orthopedic solutions. At its core, Össur's operations revolve around the invention and commercialization of cutting-edge prosthetics, braces, and supports aimed at improving the quality of life for people who face limb challenges due to injuries, disabilities, or age-related conditions. The company's ethos of "Life Without Limitations" guides its pursuit to blend medical technology and engineering in a way that restores human dignity and functionality, manifesting a unique synergy between advanced robotics and biology. Commercially, Össur thrives by leveraging its commitment to research and development, channeling substantial investment into creating high-demand products characterized by reliability, adaptability, and innovation. Revenue streams primarily flow from the sale of prosthetic limbs and associated components, together with orthopedic support products that are distributed both directly and through a network of wholesalers and medical professionals worldwide. By maintaining a diversified product line and focusing on customer-centric customization, Össur meets a significant demand within healthcare systems, insurance providers, and direct consumer markets. The company's ability to translate its scientific prowess into marketable and life-enhancing solutions has cemented its reputation as a key player in the med-tech industry, aligning financial success with a meaningful social mission.